Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 5/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14385098 | 0.88 | GAA (0.39) | LMNA | |
| SCHEMBL12123714 | 0.81 | SIGMAR1 (0.54) | METAP1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL12123719 | 0.71 | METAP1 (0.44) | METAP1LMNAMAOAKDR | |
| SCHEMBL12123713 | 0.71 | METAP1 (0.44) | METAP1LMNAKDR | |
| SCHEMBL12123712 | 0.70 | METAP1 (0.52) | METAP1 | |
| SCHEMBL14384893 | 0.69 | SIGMAR1 (0.53) | METAP1 | |
| SCHEMBL12123718 | 0.69 | METAP1 (0.51) | METAP1LMNAKDR | |
| SCHEMBL23914453 | 0.65 | HRH3 (0.42) | METAP1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL23914273 | 0.65 | CHRNA7 (0.42) | METAP1 | |
| SCHEMBL11710593 | 0.64 | POLB (0.39) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PHARMACYCLICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | MANNKIND CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290200-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | METAP1 1682/4885ADRA2A 4559/4885ADRA2B 4101/4885 |
| US-20110281850-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | METAP1 1682/4885ADRA2A 4559/4885ADRA2B 4101/4885 |
| US-20140080833-A1 | INTRACELLULAR KINASE INHIBITORS | PI4KB, BTK, LTK | METAP1 1682/4885ADRA2A 4559/4885ADRA2B 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.